Facilitation of cholinergic transmission by combined treatment of ondansetron with flumazenil after cortical cholinergic deafferentation

Abstract

We have studied the effects of concomitant blockade of 5-HT 3 and GABA A receptors on acetylcholine (ACh) release in the frontal cortex of rats with a selective cholinergic lesion. Lesions were performed by microinjection of the cholinergic toxin 192 IgG-saporin into the nucleus basalis magnocellularis. Single treatment with either the 5-HT 3 receptor antagonist ondansetron, 0.1 lg/kg, or the GABA A receptor benzodiazepine site antagonist flumazenil, 10 mg/kg, did not affect ACh release. However, the combined ondansetron þ flumazenil administration significantly increased ACh release to a similar extent as a depolarising stimulus with K + , 100 mM, at both 7 and 30 days post-lesion. Cortical perfusion with the combined ondansetron þ flumazenil treatment also increased [ 3 H]ACh efflux ''in vitro'' 30 days after lesion, suggesting that local events within the frontal cortex may participate in the interaction of ondansetron with GABAergic neurons, modulating ACh release in situations of cholinergic hypoactivity. No differences in the expression of 5-HT 3 and GABA A receptors in the frontal cortex were found after the cholinergic lesion. These results suggest that a combined ondansetron þ flumazenil treatment would contribute to restoring a diminished cholinergic function and may provide a basis for using this treatment in the therapy of cognitive disorders associated with degeneration of the cholinergic system. #

Cholinergic hypofunction impairs memory acquisition possibly through hippocampal Arc and BDNF downregulation

“…All the aforementioned groups of animals under study consisted of half number of Sham-operated rats and half number of 192 IgG-saporin-treated rats. To assess the extent and selectivity of the cholinergic lesion, AChE activity in hippocampus as described previously (Gil-Bea et al, 2004) and cholinacetyltransferase (ChAT)-ir cells in MS were measured.…”

New insight into the therapeutic role of the serotonergic system in Parkinson's disease

“…Many studies showed that 5-HT 3 antagonists enhance cognitive functions and alleviate cognitive deficits associated with aging or the drug treatments in various animal models (e.g., Morris water maze test and novel object recognition test) (Table 3) (Arnsten et al, 1997;Barnes et al, 1990;Gil-Bea et al, 2004;Hodges et al, 1996).…”

Effect of Full-Dose Ondansetron on Tobacco Use among Male Alcohol- Dependent Outpatients - A Preliminary Study

“…the 5-HT 1 , 5-HT 1B , α 1 -adrenergic, µ-opioid receptors, and α7 and α4β2 nicotinic receptors [16]. This means that this medication may have anxiolytic, antidepressant, and anti-nociceptive properties [17]; furthermore, it can cause release of acetylcholine [18]. Another postulated mechanism for the anxiolytic and antidepressant activities is that the antagonism at 5-HT 3 receptor increases the synaptic concentration of the neurotransmitter that is made available to bind elsewhere [19].…”